On Tuesday, Sana Biotechnology Inc SANA launched the preliminary outcomes from a first-in-human examine transplanting UP421, an allogeneic main islet cell remedy engineered with Sana’s hypoimmune (HIP) know-how, into a sort 1 diabetes affected person with out the usage of any immunosuppression.
The examine was performed in partnership with Uppsala College Hospital.
Outcomes of the examine at 4 weeks after cell transplantation exhibit the survival and performance of pancreatic beta cells as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin.
C-peptide ranges additionally enhance with a combined meal tolerance take a look at (MMTT), in line with insulin secretion in response to a meal.
MRI scanning additionally demonstrated a sustained sign on the transplanted cells’ web site over time, in line with graft survival.
The examine recognized no questions of safety, and the HIP-modified islet cells evaded immune responses.
Major islet cell transplantation with immunosuppression is a longtime process in kind 1 diabetes.
Allogeneic pancreatic islet cells are remoted from a deceased donor’s pancreas and transplanted right into a affected person with the aim of regular blood glucose management and insulin independence.
As with whole-organ transplants, suppression of the recipient’s immune system has traditionally been required to stop immune rejection of the allogeneic transplanted cells and resurgence of the inciting autoimmune assault.
Sana’s HIP know-how is designed to beat the immunologic rejection of allogeneic cells. In kind 1 diabetes, it additionally evades the autoimmune rejection of pancreatic beta cells.
UP421 cells had been transplanted with no immunosuppression, and the survival of the islet cells offers proof that these cells evade allogeneic and autoimmune detection.
Worth Motion: On the final verify on Wednesday, SANA inventory was up 263.60% at $6.01 through the premarket session.
Learn Subsequent:
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
